Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …

Breast cancer progression involves multiple genetic events, which can activate dominant-
acting oncogenes and disrupt the function of specific tumor suppressor genes. This article …

PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced
ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in …

INTRODUCTION Advances in DNA sequencing technology have enabled the widespread
analysis of breast tumor genomes, creating a catalog of genetic mutations that may initiate or …

Defective DNA repair by homologous recombination (HR) is thought to be a major
contributor to tumorigenesis in individuals carrying Brca1 mutations. Here, we show that …

Germ-line mutations in breast cancer 1, early onset (BRCA1) result in predisposition to
breast and ovarian cancer. BRCA1-mutated tumors show genomic instability, mainly as a …

Purpose Cisplatin is a chemotherapeutic agent not used routinely for breast cancer
treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary …

Numerous studies have tested the association between TP53 mutations in ovarian cancer
and prognosis but these have been consistently confounded by limitations in study design …

Germline mutation in either BRCA1 or BRCA2 is associated with an increased risk of
ovarian cancer, particularly the most common invasive histotype—serous carcinoma. In …

Breast and ovarian cancers are the second and fifth leading causes of cancer deaths among
women. Both breast and ovarian cancers are highly heterogeneous and are presented with …